menu search

7 best cancer stocks to invest in now

One of the most aggressive and difficult-to-treat ailments, cancer is a disease that involves the uncontrolled division and growth of ...

July 28, 2023, 7:00 am

Innate pharma to present updated interim phase 2 efficacy results of lacutamab in mycosis fungoides at the international conference on malignant lymphoma

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced ...

June 12, 2023, 1:00 am

Nkarta presents nkx019 clinical data at the european hematology association 2023 congress and 17th international conference on malignant lymphoma

7 of 10 r/r NHL patients achieved complete response (70% CR rate) following treatment with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cell...

June 10, 2023, 2:47 pm

Allogene therapeutics announces oral presentation of phase 1 data on allo-501/501a in large b cell lymphoma at the international conference on malignant lymphoma (icml) lugano

Long-Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrates Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Simil...

June 9, 2023, 10:25 pm

Kymera therapeutics announces updated clinical data from the phase 1 trials of stat3 degrader kt-333 and irakimid degrader kt-413

Data shared today in abstracts from the International Conference on malignant Lymphoma (ICML) Both prog...

June 9, 2023, 10:00 pm

Perspective therapeutics to present at the 2023 international symposium on radiopharmaceutical sciences (isrs)

Three poster presentations from Perspective Therapeutics' scientists and collaborators explore combinations of immunotherapy and targeted alpha-partic...

May 24, 2023, 8:10 am

In8bio stock price falls even as company receives fda orphan drug status for brain cancer treatment

IN8bio (NASDAQ:INAB), Inc shares slid 16% to $2.51 in early Tuesday trading after the biopharmaceutical company announced that it has received orphan ...

April 25, 2023, 10:40 am

Here’s why nassim nicholas taleb called bitcoin a ‘malignant tumor’

Nicholas Taleb lashed out at cryptocurrency and Bitcoin in a recent interview. Find out why the Black Swan author turned from Bitcoin fan to critic. R...

February 5, 2023, 11:44 am

Bitcoin or gold? beware the ‘malignant tumor,’ says ‘black swan’ guru nassim nicholas taleb

“Technology comes and goes, gold stays, at least physically. Once neglected for a brief period, Bitcoin would necessarily collapse.” … Read Full...

January 8, 2023, 10:44 pm

Gold or bitcoin? beware the ‘malignant tumor,’ says ‘black swan’ guru nassim nicholas taleb

“Technology comes and goes, gold stays, at least physically. Once neglected for a brief period, Bitcoin would necessarily collapse.” … Read Full...

January 8, 2023, 9:29 pm

Tracon pharmaceuticals doses first patient in drug trial to treat malignant tumours

TRACON Pharmaceuticals Inc (NASDAQ:TCON) said it has dosed the first patient in a Phase 1/2 trial evaluating the company's CTLA-4 antibody, YH001, in...

November 21, 2022, 8:41 am

Midatech pharma's shares shoot higher on fda fast track designation for malignant brain tumor drug

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Midatech Pharma PLC's (NASDAQ: MTP) lead drug candidate MTX110 for t...

June 1, 2022, 11:32 am

Update -- vbl therapeutics to report year-end 2021 financial results on march 23

TEL AVIV, Israel and NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused...

March 14, 2022, 9:57 am

Fda slams brakes on legend biotech's car-t therapy trial in lymphoma patients

The FDA has instituted a clinical hold on Legend Biotech Corporation's (NASDAQ: LEGN) Phase 1 trial for LB1901.  LB1901 is the company's investig...

February 15, 2022, 9:39 am

Fda slams brakes on legend biotech's car-t therapy trial in lymphoma patients

The FDA has instituted a clinical hold on Legend Biotech Corporation's (NASDAQ: LEGN) Phase 1 trial for LB1901.  LB1901 is the company's investig...

February 15, 2022, 9:39 am

Fda slams brakes on legend biotech's car-t therapy trial in lymphoma patients

The FDA has instituted a clinical hold on Legend Biotech Corporation's (NASDAQ: LEGN) Phase 1 trial for LB1901.  LB1901 is the company's investig...

February 15, 2022, 9:39 am


Search within

Pages Search Results: